Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. - Hochster,H.S.; Welles,L.; Hart,L. (Proc ASCO, 2005)